Odontogenic-Related Micro Inflammation in Patients With Hypertension and Chronic Kidney Disease: PP.15.78

Abstract

Introduction: It is known that drugs such as HMG CoA inhibitors (statins) Inhibitors of angiotensin converting enzyme (ACEI) angiotensin II receptor blockers AT1 (ARB) inhibitors calcium channel, and acetylsalicylic acid (ASA), reduced in vitro neo-intimal proliferation. Purpose: Was to analyze multivariate regression the effect of medication cardio-protective survival has on primary and secondary (AVF). Patients and Methods:We designed a retrospective cohort study of 96 hemodialysis patients with clinical evidence of dysfunction of the AVF studied by Doppler ultrasound and Fistulography: dependent variable was considered as primary and secondary survival of the AVF. The independent variables were: sex, hyperlipidemia, diabetes, anti-hypertensive medication, ischemic heart disease, etiology of ESRD, antiplatelet drug, age. Cox regression was used to analyze the Primary and Secondary Survival, adjusted for covariates. The survival rate of vascular access in relation to drugs was modeled by Kaplan-Meier test. The statistical significance was considered if p < 0.05.Results: 96 patients, 61 were men, 35 women, mean age 59 years. 24% had diabetes, 40% were taking statins, 60 patients were taking ACEI þ ARB, 13 patients beta-blockers, 4 Calcium -antagonists, 19 were not taking antihypertensive, antiplatelet drug 91 of 96, In primary survival the treatment with ACEI is a protective factor that decreases the relative risk of losing AVF in 42% (HR: 0.58, p: 0.038 HR 95% CI: (0.354 0.970) present Dyslipidemia is a risk factor that increases the probability of losing twice AVF HR: 2.192, p ¼ 0.002, HR 95% CI: (1.328 3.618). The secondary survival is greater after making ATP (HR: 0.244, p ¼ 0.0001), HR 95% CI (0.111 0, 533) and lower in patients with dyslipidemia HR: 3.547., p: 0.04, HR 95%: (1.499 8.393). Conclusions:The ATP and treatment with an ACEI are protective and decrease the relative risk of losing the AVF by 76% and 42% respectively, while presenting dyslipidemia increases the relative risk of losing access vascular more than threefold. PP.15.76 INCIDENCE OF ORTHOSTATIC HYPOTENSION IN TREATED ESSENTIAL HYPERTENSIVES